Most recently Founder, President, and CEO of MediBic, Mr. Hashimoto called Yas by his colleagues, took MediBic public where it is listed on the Japanese stock exchange. Thanks to Yas's; vision and direction, MediBic is a leading biotechnology company in Japan specializing in providing Biomarker Discovery and Pharmacogenomics (PGx) support and aiming to help implement personalized medicine in Japan. MediBic has produced several successful subsidiaries including MediBic Pharma, Asian Private Equity Capital, Anexus Pharmaceuticals, and Site Quality Inc. Yas plans to duplicate that success with TaqTik Health. He is a graduate of Osaka Medical School and a post-graduate Fellow from Harvard Medical School. Yas is the recipient of numerous awards for his work in medicine. He is fluent in Japanese and English.
- Serial Entrepreneur
- 2 successful exits
- MediBIC, IPO 2003
- GeneticLab (acquired by Transgenic 2014)
- Lecturer at Harvard Medical School